ASCO 2022 | Personalized medicine for patients with GISTs

Michael C. Heinrich, MD, OHSU Knight Cancer Institute, Portland, OR, reflects on emerging biomarkers in predicting treatment responses in patients with gastrointestinal stromal tumors, highlighting the use of circulating tumor DNA (ctDNA) to personalize treatment approaches. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.